News articles about Cerecor (NASDAQ:CERC) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerecor earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.7922140682303 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several research firms recently weighed in on CERC. ValuEngine raised Cerecor from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.
Cerecor (CERC) traded up $0.05 during trading hours on Friday, reaching $1.68. The company had a trading volume of 231,678 shares, compared to its average volume of 1,080,887. The firm has a market capitalization of $43.77, a price-to-earnings ratio of 168.00 and a beta of 2.99. Cerecor has a 52-week low of $0.34 and a 52-week high of $2.65.
In other news, major shareholder Armistice Capital Master Fund bought 45,200 shares of the stock in a transaction on Friday, November 24th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $54,240.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Armistice Capital, Llc bought 35,200 shares of the stock in a transaction on Wednesday, November 22nd. The stock was purchased at an average price of $1.20 per share, for a total transaction of $42,240.00. The disclosure for this purchase can be found here. Insiders have purchased 233,718 shares of company stock worth $219,838 over the last three months. 10.70% of the stock is owned by insiders.
WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/10/cerecor-cerc-earning-somewhat-favorable-press-coverage-analysis-shows.html.
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc and related companies with MarketBeat.com's FREE daily email newsletter.